Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012;2(3):214-26. doi:10.1158/2159-8290.CD-12-0012
Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2(1):82-93. doi:10.1158/2159-8290.CD-11-0184
Bick AG, Calvo SE, Mootha VK. Evolutionary diversity of the mitochondrial calcium uniporter. Science. 2012;336(6083):886. doi:10.1126/science.1214977
Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9. doi:10.1038/ng.2279
Pasaniuc B, Rohland N, McLaren PJ, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet. 2012;44(6):631-5. doi:10.1038/ng.2283
Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-6. doi:10.1038/nature11071
Musunuru K, Romaine SPR, Lettre G, et al. Multi-ethnic analysis of lipid-associated loci: the NHLBI CARe project. PLoS One. 2012;7(5):e36473. doi:10.1371/journal.pone.0036473
Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040-4. doi:10.1126/science.1218595
Haining N, Pulendran B. Identifying gnostic predictors of the vaccine response. Curr Opin Immunol. 2012;24(3):332-6. doi:10.1016/j.coi.2012.03.010
Hacisuleyman E, Cabili MN, Rinn JL. A Keystone for ncRNA. Genome Biol. 2012;13(5):315. doi:10.1186/gb-2012-13-5-315